A phase I/II study of a WT1-W10 immunotherapy against high-risk MDS and MDS overt AML.
Phase of Trial: Phase I/II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs WT1-W10 peptide vaccine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 08 Feb 2018 Status changed from active, no longer recruiting to completed.
- 09 Feb 2017 New trial record